Immunomedics regulatory update

IMMU received U.S. Patent No. 5,482,698 covering several pretargeting methods for detecting and treating cancerous, infectious and cardiovascular lesions.

IMMU's approach uses a large polymer carrier molecule at one or more stages of the pretargeting sequence to amplify the number of targets. ...